Sign inJoin waitlistJoin the waitlist

Eugenia Girda

Associate Chief of Surgical Officer Research, Rutgers Cancer Institute · Rutgers Health

Credentials: · · · · · ·

History

Rutgers Cancer Institute Center · Rutgers Health
Present
Rutgers Health
Present
Rutgers Health
Present

Gynecologic Oncology
University of California Davis Health
2015–2018
Obstetrics and Gynecology
Albert Einstein College of Medicine of Yeshiva University
2011–2015
Renaissance School of Medicine at Stony Brook University
2006–2010

Research

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
ESMO Open · 2022 · 289 citations
Obesity and age at diagnosis of endometrial cancer
Obstetrics and Gynecology · 2014 · 81 citations

DG
Danielle Glassman
4 papers
GG
Gary Goldberg
4 papers
Jharna Patel
4 papers · 4 as a resident
Kristen Spencer
4 papers
Nancy Chan
4 papers
Aliza Leiser
3 papers
Bradley Corr
3 papers
Floor Backes
3 papers
Janice Mehnert
3 papers
JM
Jyoti Malhotra
3 papers
Lara Hathout
3 papers
Mark Einstein
3 papers

Clinical trials

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Principal investigator · Active not recruiting · Phase 2
Rutgers, The State University of New Jersey
2018–2027
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027